Role of " @entity63 Modified Albumin" (IMA) in XXXX .

@entity1 @entity1187 @entity662 @entity1619 @entity63 @entity341 @entity1459 @entity741 @entity583
BACKGROUND: Diagnosis of @entity1187 ( @entity1187 ) is important, due to the associated very high mortality. Failure to diagnose @entity1187 is a problem both for the @entity1 and the clinicians. @entity63 modified albumin (IMA) has already been licensed by the US Food and Drug Administration for the diagnosis of suspected @entity741 . METHODS: @entity1 attending the @entity341 ( @entity341 ) within 6  h after having features of @entity1187 were selected. IMA was done on admission. Blinded to the IMA results @entity1 were fully evaluated and a diagnosis of non-ischemic @entity662 (NICP), @entity1459 ( @entity1459 ) or @entity583 ( @entity583 ) was made. Later IMA results were correlated in each group. RESULTS: Mean IMA value was 56.38      23.89  u/ml in NICP group whereas in @entity1459 group it was 89.00      7.76  u/ml and @entity583 group was 87.50      9.62  u/ml. This showed a sensitivity of 92% and specificity of 87%. The positive predictive value of the test was 88% and negative predictive value was 94%. In 16 @entity1 an early diagnosis could be made when compared with @entity1619 . Of the 89 @entity1 11 @entity1 died in hospital. The IMA value was compared between this group and the @entity1 who survived. @entity1 who died had a mean IMA value of 88.5 with a standard deviation of 5.33 whereas in @entity1 who survived the mean value was 78.26 which was not statistically significant. CONCLUSION: In conclusion the benefit of the test would be to rule out @entity1187 in @entity1 who present early to @entity341 with inconclusive diagnosis.
